← the scenic garden Protocol MAPS-1986 Schedule I Status: living · near threshold

Spirit & Soma · network morphology · United States

MAPS & the
psychedelic
renaissance

1986 — present Multidisciplinary Association for Psychedelic Studies Generativity 3

A patient, decades-long effort to bring psychedelics back into medicine and culture — turning a criminalized underground into clinical science.

1.0

Study record

Registration data
Period
1986 – present
Site
United States
Biome
Spirit & Soma
Morphology
Network
Principal
Rick Doblin
Co-investigators
(researchers & underground)

Instruments of the scene

  • the clinical trial
  • the nonprofit
  • the conference
  • the protocol

Archetypal layer

  • The New Man
2.0

Background & rationale

MAPS — the Multidisciplinary Association for Psychedelic Studies, founded in 1986 by Rick Doblin — spearheaded the patient, decades-long campaign to bring psychedelics back from criminalized taboo into legitimate medicine and culture.

Where the 1960s psychedelic movement crashed into prohibition, MAPS chose the slow institutional path: funding rigorous clinical trials (notably MDMA-assisted therapy for PTSD), training therapists, and painstakingly rebuilding scientific and regulatory credibility. The result is the "psychedelic renaissance" — a wave of serious research, shifting laws, and mainstream attention.

As a case of a marginalized idea turned into a research program through persistence and professionalism, MAPS bridges the counterculture's consciousness-expansion ambitions and twenty-first-century psychiatry and wellness culture.

2.5

Motifs

Perforate along dotted line
01psychedelics as medicine
02the clinical trial as the long game
03patient, credentialed rehabilitation of a taboo
04MDMA for trauma
05from underground to FDA
3.0

Unifying principle

Psychedelics are medicines whose benefits can be proven through rigorous clinical science; patient, credentialed research can move them from the criminalized underground into approved therapy.

3.1

Memetic forces

Why it spread
  1. a patient, science-based path to legitimize a criminalized substance gave believers a disciplined, hopeful mission across decades
  2. credible clinical results converted skeptics and funders
  3. the promise of healing trauma (PTSD) gave it moral urgency and broad appeal
4.0

Engines

Convergent · divergent

Convergent — what held it together

  • Rick Doblin's decades-long strategy and the MAPS nonprofit
  • FDA-track clinical trials
  • a coalition of researchers, therapists, and funders

Divergent — what pulled it apart

  • tension between the underground's spirituality and clinical medicalization
  • commercialization and the "psychedelic gold rush"
  • debates over safety, hype, and access
5.0

Outcome measures

Societal impact
Drove the psychedelic renaissance, moved MDMA and psilocybin toward approved therapy, and reshaped mainstream attitudes to psychedelics and mental-health treatment.
Internal dynamics
A mission-driven nonprofit executing a multi-decade legitimation strategy; disciplined and patient, bridging an underground community and the clinical establishment.
Fate
Living and near a threshold — approval, commercialization, and the tensions of mainstreaming a once-underground practice.
1986Founding
DecadesTrials
NowThreshold
6.0

Personnel & documentation

All images credited below
Portrait staff photograph of Rick Doblin, founder of MAPS.
Rick Doblin — principalRick Doblin's staff photo. Image: MAPS, CC BY-SA 4.0 · source
Rick Doblin speaking on stage at the 2018 Oslo Freedom Forum.
The conference as mediumRick Doblin at the 2018 Oslo Freedom Forum, Det Norske Teater, 29–30 May 2018. Image: Tore Sætre, CC BY-SA 4.0 · source
7.0

References

Representative, not exhaustive
  • Michael Pollan, How to Change Your Mind (2018)
  • Tom Shroder, Acid Test: LSD, Ecstasy, and the Power to Heal (2014)

Keyed to the standard published literature on this scene (representative, not exhaustive; not independently re-verified against each edition).